-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
LIBRETTO-432 Trial Results Support Comprehensive Biomarker Testing in Early-Stage Disease
Dr. Jonathan W. Goldman said that findings from the LIBRETTO-432 trial support adjuvant selpercatinib as a new standard of care for patients with early-stage RET fusion-positive NSCLC.
-
Grading Resected Invasive Squamous Cell Carcinoma of the Lung: A Practical, Globally Validated Approach Based on Tumor Budding
Drs. Mari Mino-Kenudson and Sabina Berezowska suggest that a standardized two-tier grading system presents an important step toward harmonizing LUSC grading worldwide.
-
Expanding the Role of Neoadjuvant Chemoimmunotherapy in Borderline Resectable Stage III NSCLC
Dr. Biagio Ricciuti says the findings from a recently published study evaluating neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy suggest that chemoimmunotherapy can effectively downstage borderline resectable tumors and enable curative-intent surgery in patients who might otherwise be treated with definitive chemoradiotherapy alone.
-
What Do Recent ODAC Decisions Mean for Lung Cancer Drug Development and Clinical Trial Design?
In a Q&A with ILCN, Dr. John V. Heymach addresses several rulings from the Oncologic Drugs Advisory Committee and important lessons for research teams.
-
Investigational KRAS G12D Agents Demonstrate Promising Antitumor Activity in Non-Small Cell Lung Cancer
Early findings from two clinical studies support the continued development of setidegrasib and zoldonrasib to target KRAS G12D mutations.
-
ILCN Editorial Board Member Appointed to the Thoracic Oncology Team at Winship Cancer Institute
Dr. Shirish Gadgeel has assumed new clinical and educational leadership roles at Emory University School of Medicine and the Winship Cancer Institute.
-
From Sequencing to Treatment: The Role of Comprehensive Genome Profiling, Molecular Tumor Boards in Advanced-Stage NSCLC
Citing data from the FPG500 program, Drs. Antonio Vitale and Emilio Bria write that integrating genome profiling and molecular tumor boards into daily practice is feasible and yields measurable survival benefits for patients with actionable molecular alterations.
-
Research Points to Translational Path Toward Precision Immunotherapies for EGFR-Mutant NSCLC
Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.
-
As Air Quality Protections Weaken, Advocates Call on Healthcare Community to Consider Implications for Public Health, Patient Care
Drs. Joan H. Schiller and Roselle de Guzman say championing public policies that prioritize clean air and incorporate environmental exposure histories into clinical care are the future of the field.
-
Inhaled Gene Therapy Receives FDA RMAT Designation for Advanced NSCLC
The decision was based on findings from the KYANITE-1 trial, which demonstrated that the treatment was generally well tolerated with single-agent antitumor activity observed.